Free Trial
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics logo
$4.36 -0.02 (-0.46%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$4.36 0.00 (0.00%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Verve Therapeutics Stock (NASDAQ:VERV)

Key Stats

Today's Range
$4.24
$4.40
50-Day Range
$2.97
$5.89
52-Week Range
$2.86
$9.31
Volume
1.38 million shs
Average Volume
1.86 million shs
Market Capitalization
$388.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.75
Consensus Rating
Buy

Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

VERV MarketRank™: 

Verve Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 283rd out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verve Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verve Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verve Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verve Therapeutics is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verve Therapeutics is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verve Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    27.88% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently increased by 11.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Verve Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Verve Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.88% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently increased by 11.78%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Verve Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for Verve Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    18 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,427.00 in company stock.

  • Percentage Held by Insiders

    19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verve Therapeutics' insider trading history.
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

FY2025 EPS Estimate for Verve Therapeutics Lifted by Analyst
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Research Analysts Offer Predictions for VERV FY2026 Earnings
Cantor Fitzgerald Analysts Raise Earnings Estimates for VERV
Q3 EPS Forecast for Verve Therapeutics Raised by Analyst
See More Headlines

VERV Stock Analysis - Frequently Asked Questions

Verve Therapeutics' stock was trading at $5.64 at the beginning of 2025. Since then, VERV stock has decreased by 22.7% and is now trading at $4.36.
View the best growth stocks for 2025 here
.

Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.36. The firm had revenue of $32.98 million for the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 35.23% and a negative net margin of 807.65%.

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

Top institutional shareholders of Verve Therapeutics include Vanguard Group Inc. (4.44%), Woodline Partners LP (3.10%), T. Rowe Price Investment Management Inc. (2.80%) and Millennium Management LLC (2.37%). Insiders that own company stock include Krishna Yeshwant, Fmr Llc, Andrew D Ashe, Sekar Kathiresan, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv.
View institutional ownership trends
.

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.75
High Stock Price Target
$39.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+490.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-200,070,000.00
Net Margins
-807.65%
Pretax Margin
-806.39%

Debt

Sales & Book Value

Annual Sales
$59.61 million
Price / Cash Flow
N/A
Book Value
$7.31 per share
Price / Book
0.60

Miscellaneous

Free Float
68,324,000
Market Cap
$388.66 million
Optionable
Optionable
Beta
1.82
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:VERV) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners